The FDA approved new COVID-19 vaccines to be used this fall.
In a press statement on the matter, Moderna said their Spikevax vaccine is to be used in those aged six months to 64 years old “with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.” Another vaccine for COVID-19, called mNEXSPIKE, is “approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.”
Similarly, Pfizer celebrated its vaccine’s FDA approval, as did Novavax.
“With today’s approval, we will work with our partner Sanofi to provide access to a protein-based, non-mRNA COVID-19 vaccine for eligible individuals this fall,” John Jacobs, President and Chief Executive Officer of Novavax said in a statement.
In May, the FDA Vaccines and Related Biological Products Advisory Committee met to consider whether the COVID-19 inoculation should be updated to target XFG variants.
“Recommendations for updating the strain composition of COVID-19 vaccines must consider the time needed for manufacturers to implement and deliver an updated COVID-19 vaccine formula,” briefing notes obtained by The Hill read. “The timelines likely differ for different manufacturing technologies and are also affected by manufacturing experience and the availability and capacity of manufacturing facilities. All licensed manufacturers have indicated that they are prepared to produce an XFG vaccine for COVID-19 vaccines (2026–2027 Formula).”
